chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually has chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable and treatable disease.

Chronic%20obstructive%20pulmonary%20disease Management

Monitoring

Prior to discharge from the hospital, check the patient based on the following criteria:

  • Able to use long-acting either beta2-agonists and/or anticholinergics with or without inhaled corticosteroids
  • Inhaled beta2-agonist is needed every 4 hours or less frequently
  • Able to walk across the room (if previously ambulatory)
  • Able to eat and sleep without frequent interruptions due to breathing difficulty
  • Clinically stable for 12-24 hours
  • ABG stable for 12-24 hours
  • Patient and caregiver adequately understand correct medication use
  • Home care arrangements (eg O2 delivery) are in place
  • Patient, family and physician are confident that patient can manage well

Follow Up

  • A follow-up assessment must be carried out within 4-12 weeks following discharge from hospital for exacerbations
  • Check patient’s ability to cope in his environment
  • Measure FEV1
  • Check inhaler technique
  • Check understanding and ability to follow treatment regimen
  • Assess need for long-term O2 therapy and/or home nebulizer for patients with very severe COPD
  • Check status of comorbidities
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 6 days ago

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Pearl Toh, 18 Jan 2020
Almost three-quarters of adverse events (AEs) related to medication errors in over-the-counter (OTC) cough and cold medications (CCMs) for paediatrics required evaluation by healthcare facility and majority of the cases were due to dosing errors, a surveillance study has found, highlighting the need for interventions to mitigate medication errors.
Pearl Toh, 06 Aug 2020
A fixed-dose triple therapy of ICS, LAMA, and LABA* is superior to dual therapies of either LAMA-LABA or ICS-LABA for controlling exacerbations in patients with moderate-to-very-severe COPD**, according to the large ETHOS*** trial.